Information Provided By: 
Fly News Breaks for October 29, 2015
ABMD
Oct 29, 2015 | 12:32 EDT
Sterne Agee CRT analyst Shagun Singh Chadha said Abiomed reported a "solid quarter by all measures" and attributes the pullback in shares to concerns over its growth rate and the company's ability to achieve its stretch goal of over $1B in sales by 2020. The analyst said that ongoing Impella momentum is strong and the concerns are overblown, presenting a buying opportunity. Singh Chadha keeps a Buy rating and $130 price target on Abiomed shares.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
